Cliff Asness's IKT Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 468,197 shares of Inhibikase Therapeutics, Inc. (IKT) worth $950,440, representing 0.00% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Cliff Asness has initiated a new position in IKT, representing a fresh investment thesis on this company. Largest addition occurred in Q2 2026, adding 296,184 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Inhibikase Therapeutics (IKT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Inhibikase Therapeutics (IKT) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +296,184 | Add 172.19% | 468,197 | $2.03 |
| Q1 2026 | +172,013 | New Buy | 172,013 | $1.68 |
Cliff Asness's Inhibikase Therapeutics Investment FAQs
Cliff Asness first purchased Inhibikase Therapeutics, Inc. (IKT) in Q1 2026, acquiring 172,013 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Inhibikase Therapeutics, Inc. (IKT) for 2 quarters since Q1 2026.
Cliff Asness's largest addition to Inhibikase Therapeutics, Inc. (IKT) was in Q2 2026, adding 468,197 shares worth $950,440.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 468,197 shares of Inhibikase Therapeutics, Inc. (IKT), valued at approximately $950,440.
As of the Q2 2026 filing, Inhibikase Therapeutics, Inc. (IKT) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Inhibikase Therapeutics, Inc. (IKT) was 468,197 shares, as reported at the end of Q2 2026.